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Abstract
Pathologically elevated immune activation and inflammation contribute to HIV disease pro-
gression and immunodeficiency, potentially mediated by elevated levels of prostaglandin E2,
which suppress HIV-specific T cell responses. We have previously shown that a high dose of
the cyclooxygenase-2 inhibitor celecoxib can reduce HIV-associated immune activation and
improve IgG responses to T cell-dependent vaccines. In this follow-up study, we included 56
HIV-infected adults, 28 antiretroviral therapy (ART)-naïve and 28 on ART with undetectable
plasma viremia but CD4 counts below 500 cells/μL. Patients in each of the two study groups
were randomized to receive 90 mg qd of the cyclooxygenase-2 inhibitor etoricoxib for six
months, two weeks or to a control arm, respectively. T cell activation status, HIV Gag-specific
T cell responses and plasma inflammatory markers, tryptophan metabolism and thrombin
generation were analyzed at baseline and after four months. In addition, patients received
tetanus toxoid, conjugated pneumococcal and seasonal influenza vaccines, to which IgG
responses were determined after four weeks. In ART-naïve patients, etoricoxib reduced the
density of the activation marker CD38 in multiple CD8+ T cell subsets, improved Gag-specific
T cell responses, and reduced in vitro plasma thrombin generation, while no effects were
seen on plasma markers of inflammation or tryptophan metabolism. No significant immuno-
logical effects of etoricoxib were observed in ART-treated patients. Patients receiving long-
term etoricoxib treatment had poorer tetanus toxoid and conjugated pneumococcal vaccine
responses than those receiving short-course etoricoxib. Cyclooxygenase-2 inhibitors may
attenuate harmful immune activation in HIV-infected patients without access to ART.
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Introduction
Chronic, untreated HIV infection is characterized by a state of pathological immune activation
and inflammation, which contributes to disease progression and immunodeficiency [1].
Expression of the activation marker CD38 on T cells predicts both progression to AIDS and
mortality [2–6]. When plasma viremia is suppressed to near-undetectable levels by antiretrovi-
ral therapy (ART), immune activation is attenuated, but not to the level of the HIV-uninfected
population [7, 8], and residual immune activation in patients on ART is associated with both
mortality and impaired immune reconstitution [7, 9, 10]. Of particular concern are the effects
of HIV infection on cardiovascular health, with HIV-infected patients at an increased risk of
both myocardial infarction and venous thromboembolism [11, 12].
In the absence of ART, HIV-specific CD8+ T cell function is essential for viral control [13,
14], but this is progressively lost in most chronically infected patients [15] and not restored
after ART initiation [16, 17]. In recent years, there has been an increasing focus on treatment
strategies to induce viral control post-ART, a so-called “functional cure” [18]. Most cure strate-
gies will likely rely on boosting HIV-specific CD8+ T cell function to eliminate the majority of
latently infected cells and prevent viral rebound from any remaining reservoirs [19, 20].
A major driver of HIV immunopathogenesis is the translocation of microbial products
from the gut lumen to the submucosa and circulation, due to a defective gut barrier [21].
This chronic exposure to microbial antigens such as lipopolysaccharide (LPS) activates innate
immune cells, including monocytes, macrophages and dendritic cells, inducing the enzyme
cyclooxygenase (COX) 2 and leading to increased synthesis of prostaglandin E2 (PGE2) [22–
25]. We have hypothesized that this represents one mechanism of functional suppression of T
cells in HIV infection, as PGE2 inhibits T cell activation via a cyclic AMP-/protein kinase A-
dependent mechanism [26–28]. Another enzyme induced by LPS exposure of innate immune
cells is indoleamine 2,3-dioxygenase (IDO), which catabolizes tryptophan and inhibits T cell
responses in both HIV infection and cancer [29, 30].
We have previously shown that treatment with high-dose COX-2 inhibitors (COX-2i) for
12 weeks can reduce the expression of T cell activation markers in both untreated [31] and
treated but viremic [32] HIV-infected patients, and improve IgG recall responses to a T cell-
dependent vaccine in ART-naïve patients [31]. However, in ART-naïve patients with high
levels of immune activation at baseline, celecoxib administered at twice the typically recom-
mended maximal dose (400mg bid) was also associated with a high incidence of rash. This
explorative study was performed to further characterize the immunological effects of a longer
treatment course of a COX-2i at a conventional clinical dose which would be better tolerated,
in both ART-naïve, viremic patients and ART-treated patients with suppressed plasma viremia
but suboptimal CD4 T cell reconstitution. Patients were randomized to receive 90 mg qd of
the COX-2i etoricoxib, a commonly used dose in inflammatory rheumatic disease, for six
months or two weeks, or to a control group. T cell activation status, HIV Gag-specific T cell
function, and plasma inflammatory markers, tryptophan metabolism and thrombin genera-
tion were examined at baseline and after four months, to determine the immunomodulatory
effect of long-term COX-2i treatment. The two week treatment group was included to test the
hypothesis that a short course of COX-2i could improve IgG responses to three T cell-depen-
dent vaccines, i.e. serve as a vaccine adjuvant in HIV-infected individuals.
Materials and methods
The CONSORT checklist and study protocol are available as supplementary information; see
S1 and S2 Files.
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Patient inclusion
Adult, HIV-infected patients were included from the outpatient clinic at the Department of
Infectious Diseases, Oslo University Hospital, from January 2011 through May 2014, in one of
two study groups. One group consisted of ART-naïve patients, with CD4 counts above 350
cells/μL and plasma HIV RNA above 2000 copies/mL, a confirmed diagnosis of HIV infection
less than 8 years pre-inclusion and no current indication for ART according to European
guidelines at the time [33]. The other study group consisted of patients on ART, with CD4
counts below 500 cells/μL and HIV RNA below 50 copies/mL for at least 6 months prior to
inclusion. All included patients were between 18 and 65 years of age and had no history of
symptomatic acute HIV infection within the last 12 months.
Exclusion criteria for all study participants were concomitant use of non-steroidal anti-
inflammatory drugs, corticosteroids or interferon-alpha, total cholesterol >7 mM, elevated
serum creatinine, creatinine clearance <30ml/min, hypertension, heart failure, diabetes, ische-
mic heart disease, peripheral arteriosclerosis and/or cerebrovascular disease, cardiovascular
events or stroke in parents, siblings or offspring of<55 years of age, pregnancy or insufficient
birth-control, breast-feeding, deranged liver function, inflammatory bowel disease, active pep-
tic ulcer, or gastrointestinal haemorrhage.
Study design
ART-naïve and ART-treated patients were separately randomized to one of three arms in a
2:1:1 fashion and in blocks of 20, by drawing allocation numbers from a pre-generated random
sequence to which the investigators were blinded beforehand. Arm 1 received oral etoricoxib
90 mg once daily for six months, arm 2 received oral etoricoxib 90 mg once daily for two
weeks whereas arm 3 received no drug. The study was open label. Patients were examined and
blood samples were drawn at screening, inclusion (week 0), study week 5 in arms 2/3, study
week 9 in arm 1, four months and six months.
Final analysis of immunological endpoints was performed at four months as opposed to the
protocol-ascribed six months. This was due to illness of key study personnel, leading to
delayed sampling at six months of a significant proportion of patients, after cessation of study
drug. Thus, endpoint data related to COX-2i effects beyond four months of follow-up were
incomplete. Notably, no patients discontinued the study due to adverse events or commence-
ment of ART after four months of follow-up (see Fig 1 for patient flow and Fig 2 for overview
study design).
Written, informed consent was obtained from all study participants. The study was
approved by the Norwegian Medicines Agency (EudraCT No: 2010-020382-25) and the Nor-
wegian Regional Committee for Medical and Health Research Ethics South East (application
#2010/1593). The study was registered at Clinicaltrials.gov (Identifier: NCT01269515). The
study was independently monitored for safety by Link Medical.
Endpoints
Primary endpoints were changes in CD38 density on CD8+ T cells after four months of
etoricoxib treatment and changes in IgG levels to the three study vaccines four weeks post-
vaccination. Secondary endpoints were changes in HIV Gag-induced CD8+ T cell responses
and plasma markers of inflammation, tryptophan metabolism and coagulation after four
months.
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Safety evaluation
Adverse events were registered at all study visits, and graded as non-serious/serious and likely
related to etoricoxib or not. Routine clinical biochemistry parameters were analyzed at all sam-
pling time points, and values outside reference ranges were evaluated by a clinical investigator.
Routine laboratory analyses
CD4+ and CD8+ T cell counts and plasma HIV RNA was determined at all sampling time
points by routine clinical assays.
Flow cytometry
To characterize CD8+ T cell subsets, thawed peripheral blood mononuclear cells (PBMC) were
surface-stained with αCD3 V450, αCD8 APC-H7, αCD38 PE, αPD-1 FITC, αCD45RA APC,
αCD27 PerCP Cy-5.5 and αCCR7 PE-Cy7 (all BD Biosciences, San Jose, CA), then analyzed.
To quantify regulatory T cells thawed PBMC were first incubated with Fixable Viability Stain
450 (BD), then surface-stained with αCD3 PerCP Cy-5.5, αCD4 APC-H7, αCD25 FITC,
αCD45RA APC (all BD) and αCD127 PE-Cy7 (eBioscience, San Diego, CA). Subsequently,
cells were fixed and permeabilized using the FoxP3 Buffer set (BD), followed by intracellular
staining with αFoxP3 PE (BD).
Fig 1. CONSORT flow chart.
https://doi.org/10.1371/journal.pone.0176527.g001
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The density of activation marker CD38 on CD8+ subsets was determined by the Quantibrite
method [34]. The αCD38 PE monoclonal antibody (mAb) used to stain CD8+ T cells had
>95% 1:1 PE:mAb ratio. By comparing PE MFI with that of Quantibrite beads (BD) with four
known densities of PE, the number of CD38 molecules per CD8 cell was calculated.
To quantify HIV-specific CD8+ T cell effector responses, thawed PBMC were rested over-
night and tested for viability by Muse Count and Viability Assay (Merck Millipore, Darmstadt,
Germany) before stimulation with an overlapping, 15-mer HIV Gag peptide pool (PepMix
HIV Gag Ultra, JPT Peptide Solutions, Berlin, Germany) at a final concentration of 2 μg/mL/
peptide. Costimulatory antibodies αCD28 and αCD49d (1 μg/mL; BD), brefeldin A (Golgi-
Plug, 1 μL/mL; BD), monensin (GolgiStop; 0,67 μL/mL; BD), and αCD107a PE were added at
the start of the stimulation. Unstimulated and positive controls (Staphylococcal enterotoxin B,
1 μg/mL; Sigma-Aldrich) were included for all samples. Cells were incubated for 5.5 hours at
37˚C, incubated with Fixable Viability Stain 450, fixed and permeabilized using BD Cytofix/
Cytoperm, and stained with αCD3 PerCP, αCD8 APC-H7, αIL-2 APC, αIFN-γ PE-Cy7,
αMIP-1β FITC and αTNF-α BV605 (all BD).
Cells were analyzed on a BD FACS Canto II flow cytometer, data was acquired using FACS
Diva 6.1 (BD) and analyzed using FlowJo X (FlowJo LLC, Ashland, OR). Gating of non-dis-
crete populations was done using fluorescence minus-one (FMO) controls, where appropriate.
Examples of all gates are included in S1 Fig.
CD8 effector responses were background-subtracted using the unstimulated control, with
responses <0.01% adjusted to 0. Polyfunctional subsets were defined by Boolean gating, while
a total Gag-specific response was calculated by summing all 4 cytokine responses and the
CD107a response per sample. Polyfunctional response data were graphed and analyzed in
SPICE (M Roederer, NIH, [35]).
Fig 2. Study overview. COX-2i treatment duration indicated in grey. S, blood sampling; V, vaccination.
https://doi.org/10.1371/journal.pone.0176527.g002
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Plasma soluble markers
Soluble (s)CD25, sCD163, sCD14, interleukin (IL) 6 (high sensitivity), interferon-inducible
protein (IP) 10 and C-reactive protein (CRP) were measured in cryopreserved EDTA plasma
by ELISA (R&D Systems, Stillwater, MN).
Coagulation analyses
Thrombin formation in cryopreserved citrate plasma was assayed using the CAT assay [36]
according to the user manual provided by Thrombinoscope B.V (Maastricht, The Nether-
lands). From the CAT assay we analyzed the parameters ETP, ie. the area under the thrombin
generation curve and Peak, the maximum concentration of thrombin. Coagulation was trig-
gered by recalcification of plasma in the presence of 5 pM recombinant, relipidated human tis-
sue factor (PPP-reagent, Thrombinoscope B.V), and 417 μM fluorogenic substrate (FluCa,
Thrombinoscope B.V). Fluorescence was monitored using the Fluoroscan Ascent fluorometer
(ThermoLabsystems, Helsinki, Finland), and the thrombin generation parameters were calcu-
lated using the Thrombinoscope1 software (Thrombino-scope B.V). In order to increase
reproducibility all CAT-derived parameters were normalized by dividing the measured test
value with that of reference plasma pooled from 34 healthy adults run in the same assay.
Free protein S, free Tissue Factor Plasminogen Inhibitor (TFPI) and D-dimer were ana-
lyzed in cryopreserved citrate plasma using commercial ELISA kits (Zymutest free protein
S from Hyphen Biomed, Neuville Sur Oise, France; Asserachrom1 Free TFPI and Assera-
chrom1 D-Dimer from Diagnostica Stago, Asnières, France).
LC-MS K/T ratio
Plasma concentrations of tryptophan and its metabolite kynurenine in cryopreserved EDTA
plasma were analyzed by liquid chromatography—tandem mass spectrometry by Bevital AS
(Bergen, Norway) [37].
Vaccination substudy
To investigate the effect of long-term vs. short-course etoricoxib treatment on vaccine
IgG responses, study participants received the following three T cell-dependent vaccines at
study week 5 (arm 1) and study week 1 (arms 2/3): seasonal influenza virus type A/B vaccine
(Fluarix, GlaxoSmithKline, Brentford, UK), tetanus toxoid vaccine (Tetavax, Sanofi Pasteur
MSD, Swiftwater, PA) and 13-valent pneumococcal conjugate vaccine (Prevenar 13, Pfizer,
New York, NY). Participants who had received one of the study vaccines within the preceding
2 years were not re-vaccinated and were excluded from analysis of responses to the vaccine in
question. Vaccine-specific IgG levels were measured in cryopreserved sera at baseline and 4
weeks after vaccination (study week 9 for arm 1, study week 5 for arms 2/3).
IgG antibodies to tetanus toxoid were quantified by ELISA. Sera were tested at two-fold
dilutions, and antibody levels were determined according to the International Standard for
Tetanus Immunoglobulin (Human WHO TE-3, NIBSC, Hertfordshire, UK). IgG antibody lev-
els above 0.1 IU/mL were considered protective. All sera from a given patient were run on the
same plate.
Total IgG antibodies to a mix of 23 pneumococcal polysaccharides (PPV23, Pneumovax,
Sanofi Pasteur MSD), were measured by ELISA after Cell Wall Polysaccharide (CWPS)
adsorption of sera (PnC C-PS Pneumococcal C polysaccharide, Statens Serum Institut, Copen-
hagen, Denmark). The IgG antibody levels to PPV23 were given as arbitrary units (U/mL),
according to an in-house standard. All sera from a given patient were run on the same plate.
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Serum antibody titers to influenza virus A/H1N1pdm09 were detected by influenza hemag-
glutination inhibition (HI) assay. This antigen was included in all the seasonal influenza vac-
cines given in this study. Sera were tested in serial two-fold dilutions starting at 1:10 with
turkey red blood cells as indicator cells [38]. The HI titer is defined as the reciprocal value of
the highest serum dilution that produces complete inhibition in the assay. An antibody
titer 40 was considered protective [39].
Statistical analysis
All statistical methods used were non-parametric. Differences in proportions were evaluated
with chi-square tests. The effects of etoricoxib treatment were evaluated by comparing changes
in variables (Δ) at four months of etoricoxib treatment between treatment arms within the
ART-naïve and ART-treated groups separately. To increase statistical power, and as the wash-
out period of etoricoxib effects on immunological parameters was considered to be in the
order of days (t1/2 approx. 22 hours), the arms receiving two weeks of etoricoxib and no study
drug were combined in analysis of immunological effects at four months. In analysis of vaccine
responses at four weeks post-vaccination, the three treatment arms were analyzed separately,
to evaluate the effect of short-term etoricoxib treatment as a vaccine adjuvant, compared to
continuous etoricoxib therapy. COX-2i-related changes in immunological variables in all
treatment arms are given in S1 Table. P-values <0.05 were considered statistically significant.




A total of 28 ART naïve patients and 28 patients suppressed on stable ART were included in
the study (clinical data in Table 1). After baseline, six patients in the ART naïve group inter-
rupted the study, four due to an indication for ART initiation according to guidelines at the
time and two due to non-serious adverse events (exacerbation of a pre-existing rash and oral
blisters, respectively). One patient in the ART-treated group interrupted the study due to a
deep vein thrombosis diagnosed a few days after commencing etoricoxib. Patient-reported
compliance in taking etoricoxib was>95%.
Modified analysis due to baseline difference in CD4 count but no effect of
COX-2i on clinical variables
Comprehensive analysis of etoricoxib effects showed minimal differences between patients
receiving long-term etoricoxib (arm 1) and controls (arm 2+3) within both the ART-naïve and
ART-treated study groups. However, despite randomization, there were significant baseline
differences in CD4 counts (p = 0.04) and CD4/CD8 ratio (p = 0.03) between treatment arms in
the ART-naïve study group and similar evidence for a more advanced disease phenotype in
ART-treated patients (Fig 3). While this baseline difference in key immunological markers was
likely due to chance, we hypothesised that that it might significantly impact on study out-
comes. Further analysis of etoricoxib effects after four months was therefore restricted to
patients with a CD4/CD8 ratio < 0.6 (75th percentile in the whole cohort), rendering all base-
line clinical data baseline similar between the intervention arms, including CD4 counts and
CD4/CD8 ratios (ART-naïve: median CD4 count 493 vs. 513, p = 0.39 and median CD4/CD8
ratio 0.39 vs. 0.45, p = 0.53, respectively. ART-treated: median CD4 count 361 vs. 358, p = 0.45
and median CD4/CD8 ratio 0.35 vs. 0.41, p = 0.31, respectively).
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We nevertheless observed no effect of four months of etoricoxib treatment on CD4 counts
or CD4/CD8 ratio, in ART-naïve or ART-treated patients. There was no effect of etoricoxib on
HIV viremia in ART-naïve patients, or on viral load blips in ART-treated patients (data not
shown).
COX-2i reduces CD38 density in ART-naïve patients
As expected, the ART-naïve group had higher baseline expression of the activation marker
CD38 on CD8+ T cells, both as frequency of positive cells and as CD38 density (molecules/cell,
p<0.001, and tended to have higher expression of PD-1 on CD8+ T cells (% positive, p = 0.06)
than the ART-treated group (Table 2).
In ART-naïve patients, long-term etoricoxib treatment reduced the density of activation
marker CD38 in CD8+, CD8+HLADR+, and CD8+PD-1+ subsets (p = 0.015, p = 0.04 and
p = 0.008, respectively, see Fig 4A). No effect on PD-1 expression on CD8+ T cells was
observed (Fig 4A), nor on the relative frequency of naïve and memory CD8+ T cell subsets
(data not shown). In contrast, etoricoxib did not significantly affect the expression of activa-
tion, exhaustion or differentiation markers on CD8+ T cells in ART-treated patients (Fig 4A).
Frequencies of both total (CD4+CD25hiCD127loFoxP3+) and activated (CD4+CD25hiC-
D45RA-FoxP3+) Tregs were lower in the ART-naïve group than the ART-treated group at
baseline (2.8 vs. 4.3%, p = 0.03 and 2.1 vs. 3.3%, p = 0.007, respectively), but there was no effect
of etoricoxib on the frequency of Tregs in either study group (data not shown).
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1Data given as median and lower/upper quartile
2 Mann-Whitney U test
3 Chi-square test
https://doi.org/10.1371/journal.pone.0176527.t001
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COX-2i enhances HIV Gag-specific T cell responses
In terms of HIV-specific immunity, the baseline total CD8+ T cell response to Gag stimulation
was higher in the ART-naive group (p = 0.046, Table 2). When the response was broken down
into polyfunctional subsets and the prevalent subsets were analyzed separately, CD107a+MIP-
1β+IFN-γ+ and CD107a+MIP-1β+ responses were significantly higher in the ART-naïve group
compared with the ART-treated group (median 0.098% vs. 0.037%, p = 0.001 and median
0.066% vs. 0.038%, p = 0.04, respectively).
In ART-naïve patients, etoricoxib significantly increased the frequency of the HIV Gag-
induced CD8+CD107a+MIP1β +IFN-γ+ T cell subset (p = 0.04) and possibly increased the
CD8+CD107a+MIP1β + subset (p = 0.08, Figs 4B and 5). Furthermore, the total Gag-induced T
cell response as the proportion of CD8+ T cells appeared greater in ART-naïve patients treated
with etoricoxib, but this effect was not statistically significant (p = 0.16, Fig 4B). No effect on
HIV-specific T cell immunity was seen in the ART-treated study group.
COX-2i does not modulate soluble markers of inflammation
Of the plasma soluble markers of inflammation assayed, the ART-naïve group had higher base-
line levels of sCD25, IP10 and CD163 (all p<0.001), but not of CD14, IL-6 and CRP, than the
ART-treated group (Table 2). There was, however, no effect of etoricoxib on any these markers
in either patient group (Fig 4C).
Effect of COX-2i on tryptophan metabolism
At baseline, the ART-naïve group had higher plasma levels of tryptophan catabolite kynure-
nine and a higher kynurenine/tryptophan (K/T) ratio than the ART-treated group (p = 0.003
and p = 0.004, respectively, Table 2). Etoricoxib significantly reduced plasma levels of
Fig 3. Baseline CD4+ T cell count and CD4/CD8 ratio. P-values derived from comparison of all included patients. For analysis of immunological effects of
COX-2i after four months, arms 2 and 3 were combined (denoted Long-term COX-2i -), and patients with a CD4/CD8 ratio >0.6 (light grey color) were
excluded. Median and lower/upper quartile indicated.
https://doi.org/10.1371/journal.pone.0176527.g003
Immunomodulation by COX-2 inhibitors in untreated and ART-treated HIV infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0176527 May 2, 2017 9 / 20
Table 2. Baseline immunological parameters.
ART-naïve Arm 1 vs.
Arm 2/3
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Arms 2/3 p-value ALL Arm 1 (COX-2i
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Arms 2/3 p-value p-value
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1Data given as median and lower/upper quartile
2 Mann-Whitney U test
https://doi.org/10.1371/journal.pone.0176527.t002
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kynurenine in ART-naive patients (p = 0.049, Fig 4D), but there was no significant effect on
IDO activity, as defined by the K/T ratio. No effect on tryptophan metabolism was observed in
ART-treated patients.
Fig 4. Change (Δ) in immunological variables from baseline to four months. ART use and long-term COX-2i treatment indicated. Data given as median
and lower/upper quartile. A: T cell activation, B: Gag-induced CD8 T cell responses, C: Plasma inflammatory markers, D: Tryptophan metabolism, E:
Coagulation.
https://doi.org/10.1371/journal.pone.0176527.g004
Immunomodulation by COX-2 inhibitors in untreated and ART-treated HIV infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0176527 May 2, 2017 11 / 20
COX-2i reduces ex vivo thrombin generation in ART-naïve patients
When plasma thrombin generation was assessed, ART-naïve patients had lower Endogenous
Thrombin Potential (ETP) and Peak than ART-treated patients (p = 0.013 and p = 0.004,
respectively, Table 2). There was some evidence for higher free Protein S in plasma in ART-
naïve patients (p = 0.08), but no difference in plasma D-dimer or free TFPI.
In ART-naïve patients, etoricoxib treatment reduced ETP and there was a trend of reduced
Peak (p = 0.04 and p = 0.08, respectively, Fig 4E), but there was no effect of etoricoxib on
plasma levels of free TFPI, free Protein S or D-dimer. No effect of etoricoxib on any of the
assayed coagulation parameters was observed in ART-treated patients.
Effect of COX-2i on vaccine antibody responses
In the ART-naïve and ART-treated groups, respectively, 25 and 28 patients received a tetanus
toxoid vaccine, 22 and 23 received a seasonal influenza vaccine, and 25 and 26 patients
received a 13-valent conjugated pneumococcal vaccine.
All patients but one had protective tetanus toxoid IgG levels of>0.1 IU/mL at baseline,
indicating previous vaccination. Four weeks after vaccination, IgG levels increased by a factor
of 2.4 (IQR 1.5–4.0, p<0.001) in both ART-naïve and ART-treated patients. ART-naïve
patients receiving four months of etoricoxib had less of an antibody increase at week 4 post-
vaccination than the arm receiving two weeks of etoricoxib (p = 0.03, Fig 6), with no difference
between either treatment arm and the control arm. No significant effects of etoricoxib were
found in the ART-treated study group.
Sixteen ART-naïve patients (57%) and 14 ART-treated patients (50%) had previously
recorded vaccination with a 23-valent pneumococcal polysaccharide vaccine, but no patients
Fig 5. Polyfunctional responses of CD8+ T cells after stimulation with an HIV Gag peptide pool. A: Two prevalent polyfunctional subsets
(CD107a+MIP1β+IFN-γ+ and CD107a+MIP1β+) increased after four months of etoricoxib in ART-naïve patients. ART and COX-2i use indicated, coloured bar
pairs represent response at baseline and four months, respectively. B: The CD8+ T cell response tended to be more polyfunctional after four months of
etoricoxib in ART-naïve patients (2 leftmost pies). P-values derived from unpaired permutation tests.
https://doi.org/10.1371/journal.pone.0176527.g005
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had previously received the 13-valent conjugated pneumococcal vaccine. However, there was
no significant difference in IgG levels at baseline or 4 weeks after administration of a 13-valent
conjugated pneumococcal vaccine between previously vaccinated and unvaccinated patients
(data not shown). Once again, ART-naïve patients receiving four months of etoricoxib had a
smaller increase in IgG levels four weeks after vaccination than the corresponding two week
etoricoxib arm (p = 0.05, Fig 6), while there was no difference between either etoricoxib arm
and the control arm. No significant effect of etoricoxib treatment on pneumococcal vaccine
IgG responses was found in the ART-treated study group.
At study baseline, 4 ART-naïve and 13 ART-treated patients (18% vs. 57%, respectively,
p = 0.04) had protective influenza H1N1 IgG titers (>40), due to previous exposure to swine
flu or vaccination with the same antigen. Of patients without pre-existing protective IgG levels,
11 ART-naïve and 7 ART-treated patients had protective IgG levels 4 weeks after vaccination
(61% vs. 70%, p = 0.64), and no significant effect of etoricoxib treatment on influenza vaccine
IgG levels was observed in either study group (data not shown).
Discussion
The objective of this study was to explore the immunological effects of conventional doses of
a COX-2 inhibitor, etoricoxib, in both untreated HIV-infected patients and in patients on
ART with viral suppression but suboptimal CD4 reconstitution. In ART-naïve patients who
received long-term etoricoxib, we observed a reduced density of activation marker CD38 on
CD8+ T cells, enhanced HIV Gag-induced CD8+ T cell effector responses and reduced throm-
bin generation in plasma. However, in this patient group, no effects of etoricoxib on plasma
markers of inflammation or tryptophan metabolism were observed. In this first study of a
COX-2 inhibitor in ART-treated patients with suboptimal CD4 reconstitution, no significant
effects of etoricoxib were observed.
Several markers of immune activation are predictive of clinical endpoints in HIV infection.
In this and previous investigations of COX-2i, we quantified the density of CD38 molecules on
Fig 6. Vaccine IgG antibody responses. Fold change (FC) of tetanus toxoid and conjugated pneumococcal vaccine IgG levels in
serum from baseline to 4 weeks post-vaccination, according to ART use and COX-2i treatment arm. All patients vaccinated in the
study were included the analysis. Median and upper quartile indicated.
https://doi.org/10.1371/journal.pone.0176527.g006
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CD8+ T cells and used this marker as a primary endpoint [31]. Although somewhat more labo-
rious, this marker has been shown to be more predictive of disease progression than the more
commonly used co-expression of CD38 and HLA-DR [6]. We have previously shown a reduc-
tion in CD38 density on CD8+ T cells in ART-naïve, HIV-infected patients after 12 weeks of
high-dose celecoxib [27], but this was associated with a high incidence of rash. Our current
data support that even a conventional, well-tolerated dose of COX-2i can reduce immune acti-
vation markers in ART-naïve patients. The 90 mg of etoricoxib qd administered in this study
is a routine clinical dose used for pain relief in arthritic conditions, while patients in the cele-
coxib trial received 400mg bid, a dose only indicated in familial adenomatous polyposis.
In the current study, etoricoxib did not, however, reduce immune activation markers in
aviremic patients on ART. In a previous study of rofecoxib and celecoxib in ART-treated
patients, there was evidence of reduced CD38 expression on CD8 T cells only in the few
patients with residual plasma viremia and higher baseline CD38 expression [32]. Thus, COX-
2i may have a limited potential to further reduce immune activation in ART-treated patients
with suppressed plasma viremia.
While T cell activation is a prerequisite for an effective adaptive immune response, the gen-
eralized hyperactivation seen in HIV infection is accompanied by compromised function, at
least of HIV-specific T cell clones [15–17]. We hypothesized that COX-2i may improve HIV-
specific T cell function by reducing PGE2 exposure of T cells, and did observe small increases
in the relative frequency of prevalent polyfunctional Gag-induced CD8 subsets in ART-naïve
patients who received etoricoxib. CD8 responses directed towards Gag epitopes have been
repeatedly associated with viral control in untreated HIV infection [40–42] and polyfunctional
CD8 responses are characteristic of patients with a non-progressor phenotype [43]. Thus, the
apparent boosting of Gag responses we observe in this study may potentially prove beneficial
for HIV-infected patients without access to ART. However, any clinical significance of these in
vitro observations can only be ascertained in larger studies with longer observation periods.
HIV-associated inflammation is also reflected by elevated levels of plasma markers such as
pro-inflammatory cytokine IL-6 and monocyte activation marker sCD14, which both pre-
dicted mortality in the SMART trial of intermittent vs. continuous ART [44, 45]. Comparing
ART-naïve and ART-treated patients at baseline, we observed no difference in plasma levels of
IL-6, sCD14 or CRP. This was unexpected in the case of IL-6, which has previously been found
at higher levels in untreated patients [46], and CRP, which has in fact been found elevated in
patients on suppressive ART compared to untreated patients [47]. The fact that the ART naïve
patients in our study had relatively high CD4 counts while the ART-treated patients were
selected based on suboptimal CD4 counts (median 529 vs. 364, respectively) may partly
explain these observations. Our finding of comparable levels of sCD14 between patients off
and on ART, however, is in line with other reports [48, 49]. Also consistent with these other
studies was the elevated levels in ART-naïve patients of the other monocyte activation marker
assayed, sCD163, as well as the more general markers of inflammation, IP10 and sCD25.
Treatment with etoricoxib, however, did not affect the plasma levels of these inflammatory
markers, in ART-naïve or ART-treated patients. As CD14 is shed from monocytes on exposure
to bacterial lipopolysaccharide (LPS), sCD14 is often used as a surrogate marker of microbial
translocation from the gut [50]. The fact that etoricoxib did not affect plasma levels of sCD14
or any of the other inflammatory markers in this study may suggest limited effects of COX-2
inhibition on the gut barrier. This is in line with our previous study, where no change in
plasma LPS was observed after celecoxib treatment of ART-naïve patients [31]. Interestingly, a
short course of low-dose aspirin (an irreversible inhibitor of both COX-1 and COX-2) has
been reported to reduce plasma sCD14, as well as CD38/HLA-DR expression on T cells and
platelet reactivity in HIV-infected, ART-treated patients [51].
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Another aspect of HIV-related immune dysregulation is the induction of the tryptophan-
catabolizing enzyme IDO in innate immune cells by interferon-γ and Toll-like receptor stimu-
lation. IDO upregulation has been implicated in the suppression of T cell responses as well as
skewing the Th17/Treg balance towards increased frequencies of Tregs, which may contribute
to gut barrier dysfunction and thus drive systemic inflammation in HIV infection [29]. IDO
activity, as defined by the kynurenine/tryptophan ratio in plasma, is associated with progres-
sion of untreated HIV disease [29] and with poor CD4 reconstitution and mortality in ART-
treated patients [52, 53]. In keeping with these studies, we observed a higher K/T ratio in ART-
naïve than ART-treated patients. While there was a small reduction in plasma kynurenine in
ART-naïve patients on etoricoxib, this effect was not significant when plasma tryptophan was
taken into account. Furthermore, there was no effect of etoricoxib on IDO activity in ART-
treated patients, nor any etoricoxib-related change in circulating Treg frequencies after etori-
coxib treatment in either group.
HIV infection is associated with a state of hypercoagulability [54, 55], and elevated plasma
levels of the fibrin degradation product D-dimer were strongly associated with both cardiovas-
cular disease and all-cause mortality in the SMART trial [45, 56]. At baseline, we here found
evidence of a pro-thrombotic phenotype in ART-naïve compared to ART-treated patients,
which is in accordance with a number of previous studies, including SMART [57–59]. Some-
what surprisingly, and in contrast to previous studies, we did not measure lower plasma D-
dimer in ART-treated patients. Once again, the large difference in baseline CD4 counts
between ART-naïve and ART-treated patients in our study may have contributed to this.
COX-2i and most other non-steroidal anti-inflammatory drugs are associated with a small
increase in the risk of cardiovascular events, particularly in patients with established cardiovas-
cular disease [60]. However, we hypothesized that the anti-inflammatory effect of COX-2i
could result in a net positive effect on cardiovascular risk in HIV-infected patients. In support
of this notion, we did observe a reduction in thrombin generation in ART-naïve patients
receiving etoricoxib. This may indicate a reduced risk of thromboembolic events, although the
clinical significance of in vitro thrombin generation, particularly in hypercoagulable states, has
not been firmly established [61].
A final hypothesis was that in the setting of HIV-associated immune hyperactivation, COX-
2i may improve T cell help in stimulating B cells to produce vaccine antibodies. In keeping
with this, we have previously observed improved IgG recall responses after tetanus toxoid vac-
cination in ART-naïve, HIV-infected patients receiving high-dose celecoxib [31]. However, in
the current study long-term COX-2i therapy was associated with the poorest IgG responses to
both tetanus toxoid and conjugated pneumococcal vaccines. While this discrepancy may be
due to a lower dose of COX-2i in this study, a number of in vitro studies suggest that COX-2i
have the potential to directly inhibit antibody production in B cells [62–64], which may trump
T cell help in influencing the vaccine antibody response. An alternative explanation, given the
improved Gag-induced CD8+ T cell responses we observed in ART-naïve etoricoxib-treated
patients, is that COX-2i facilitate a Th1-polarization of the T cell response, reducing B cell help
by T follicular helper cells. This could imply a potential enhancement of vaccine-specific CD8+
T cell responses with COX-2i treatment. Thus, our data suggest that COX-2i may modulate
humoral and cellular vaccine responses differently in HIV-infected patients, which warrants
further investigation in future studies.
This exploratory trial included a limited number of patients in several arms and the end-
point analysis unfortunately had to be performed after four as opposed to the per-protocol six
months. Both these factors limit the study’s power to determine moderate effects of etoricoxib.
The baseline differences in CD4 count and CD4/CD8 ratio between the treatment arms were
unfortunate, and could potentially have been avoided by incorporating stratification on
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baseline CD4 count into the randomization procedure [65]. While the purpose of our modi-
fied analysis was to make the treatment arms more immunologically comparable, excluding
patients in this manner may potentially negate some of the benefits of randomization. Further-
more, given the analysis of multiple primary and secondary endpoints, marginally significant
p-values must be interpreted with caution.
Considering our hypothesis that PGE2 from activated innate immune cells plays a central
role in COX-2-related immunomodulation, the study would have been strengthened by a
characterisation of circulating monocytes and dendritic cells, particularly with regard to acti-
vation status, COX-2 expression and functional measures such as in vitro eicosanoid secretion
in response to TLR agonists. Quantifying circulating levels of PGE2 and metabolites may also
be relevant in future studies, although interpretation may be difficult due to short plasma half-
lives [66] and whether plasma levels reflect biological effects in lymphoid tissues.
In conclusion, our results suggest that a conventional dose of a COX-2 inhibitor is safe in
HIV-infected patients both on and off ART, and has potentially beneficial effects in untreated
patients, on both generalized hyperactivation and HIV-specific function of CD8+ T cells, as
well as a possible antithrombotic effect. We did not, however, observe comparable effects in
patients with suboptimal immune reconstitution despite viral suppression on ART. While
ART is now recommended for all HIV-infected patients, and global ART coverage is steadily
improving, COX-2i or non-selective COX inhibitors could play a role in limiting immunologi-
cal pathology in selected patients not accessing ART. However, the large clinical trials needed
to establish any clinically relevant benefit of COX-2i treatment in this setting may not be
feasible.
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